Skip to main content

NeuroMetrix Reports DPNCheck® Expansion in China

Written by Customer Service on . Posted in Public Companies.

WOBURN, Mass., July 09, 2020 (GLOBE NEWSWIRE) — NeuroMetrix, Inc. (Nasdaq: NURO) today announced expanded distribution in China for DPNCheck, a fast, accurate and quantitative nerve conduction test for evaluation of peripheral neuropathies such as diabetic peripheral neuropathy (DPN).
DPNCheck was launched in China in 2016 by Omron Medical (Beijing) Ltd. (“Omron”), the Company’s exclusive China distributor. In addition to DPNCheck, Omron markets a wide range of medical products with a particular focus on diabetes and metabolic issues. Omron has been a leader in the establishment of comprehensive metabolic testing centers in hospitals with a large diabetes population. Currently there are over 300 China hospitals offering an Omron-designed Metabolic Management Center (MMC) which encompasses DPNCheck testing.  Omron recently entered a collaboration with Yabao Pharmaceutical Co., Ltd (“Yabao”) for marketing DPNCheck initially in north China, Shanxi Provence, and potentially in a broader territory. Yabao is a top 100 Chinese pharmaceutical company, listed on the Shanghai exchange, with annual revenues of about $425M and a sales force of about 3,000 employees. It is focused on chronic diseases affecting the elderly, women, and children, including those with diabetes. Omron and Yabao will address the opportunity in north China to improve patient care for diabetic neuropathy involving DPNCheck and Yabao pharmaceutical products.“Omron Medical is pleased to join with Yabao in bringing improved care to patients with health complications from diabetes,” said Mr. Yao Zhao, CEO of Omron Healthcare China. “DPNCheck plays an important diagnostic role in diabetic neuropathy, thereby facilitating more effective patient treatment with Yabao pharmaceutical products.”        About DPNCheckDPNCheck is a fast, accurate, and quantitative nerve conduction test that is used to evaluate peripheral neuropathies such as diabetic peripheral neuropathy (DPN). It is designed to be used by clinicians at the point-of-care to objectively detect, stage, and monitor DPN. More information is available at www.dpncheck.com.About NeuroMetrixNeuroMetrix is a leading developer and manufacturer of diagnostic and therapeutic neurostimulation-based medical devices that are used throughout the world.  The Company has three FDA cleared commercial products.  DPNCheck® is a point-of-care test that is used to evaluate peripheral neuropathies.  ADVANCE™ is a point-of-care device that provides nerve conduction studies as an aid in diagnosing and evaluating patients suspected of having focal or systemic neuropathies.  Quell® 2.0 is a wearable, mobile app enabled, neurostimulation device indicated for symptomatic relief and management of chronic pain and is available over-the-counter.  For more information, visit NeuroMetrix.com.NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.comSource: NeuroMetrix, Inc.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.